Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 1
1966 1
1968 1
1969 4
1970 6
1971 9
1972 7
1973 1
1974 3
1975 6
1976 6
1977 3
1978 10
1979 3
1980 5
1981 7
1982 8
1983 7
1984 6
1985 8
1986 4
1987 11
1988 15
1989 9
1990 10
1991 6
1992 8
1993 3
1994 8
1995 16
1996 9
1997 13
1998 6
1999 10
2000 13
2001 16
2002 7
2003 13
2004 11
2005 18
2006 10
2007 15
2008 17
2009 27
2010 18
2011 28
2012 26
2013 30
2014 41
2015 30
2016 22
2017 25
2018 20
2019 20
2020 30
2021 33
2022 19
2023 25
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Results by year

Filters applied: . Clear all
Page 1
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU. Versluis JM, et al. Among authors: eriksson h. Ann Oncol. 2023 Apr;34(4):420-430. doi: 10.1016/j.annonc.2023.01.004. Epub 2023 Jan 18. Ann Oncol. 2023. PMID: 36681299 Clinical Trial.
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, Blank CU. Rozeman EA, et al. Among authors: eriksson h. Nat Med. 2021 Feb;27(2):256-263. doi: 10.1038/s41591-020-01211-7. Epub 2021 Feb 8. Nat Med. 2021. PMID: 33558721 Clinical Trial.
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Schulman S, et al. Among authors: eriksson h. Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16. Circulation. 2014. PMID: 24344086 Free article. Clinical Trial.
[Unconsciousness].
Kallela M, Häppölä O, Eriksson H. Kallela M, et al. Among authors: eriksson h. Duodecim. 2014;130(4):368-82. Duodecim. 2014. PMID: 24673006 Review. Finnish.
Duodenal focal lymphangiectasia.
Yamamoto S, Eriksson H, Hedenström P. Yamamoto S, et al. Among authors: eriksson h. Dig Liver Dis. 2019 Sep;51(9):1344. doi: 10.1016/j.dld.2019.05.037. Epub 2019 Jun 26. Dig Liver Dis. 2019. PMID: 31253488 No abstract available.
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU. Rozeman EA, et al. Among authors: eriksson h. Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. Lancet Oncol. 2019. PMID: 31160251 Clinical Trial.
A Mapping Review of Netnography in Nursing.
Salzmann-Erikson M, Eriksson H. Salzmann-Erikson M, et al. Among authors: eriksson h. Qual Health Res. 2023 Jul;33(8-9):701-714. doi: 10.1177/10497323231173794. Epub 2023 May 16. Qual Health Res. 2023. PMID: 37192601 Free PMC article. Review.
Reply to E. Hindié.
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Maurichi A, et al. Among authors: eriksson h. J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701413 Free PMC article. No abstract available.
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Fan R, Satilmis H, Vandewalle N, Verheye E, De Bruyne E, Menu E, De Beule N, De Becker A, Ates G, Massie A, Kerre T, Törngren M, Eriksson H, Vanderkerken K, Breckpot K, Maes K, De Veirman K. Fan R, et al. Among authors: eriksson h. Blood Cancer J. 2023 Dec 18;13(1):188. doi: 10.1038/s41408-023-00962-z. Blood Cancer J. 2023. PMID: 38110349 Free PMC article.
689 results